Jupiter Asset Management Ltd. Lowers Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Jupiter Asset Management Ltd. decreased its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 23.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 331,584 shares of the biotechnology company’s stock after selling 99,683 shares during the quarter. Jupiter Asset Management Ltd. owned approximately 0.21% of Ironwood Pharmaceuticals worth $3,525,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Ironwood Pharmaceuticals by 1.2% in the 1st quarter. BlackRock Inc. now owns 14,536,759 shares of the biotechnology company’s stock valued at $182,873,000 after buying an additional 167,869 shares during the period. State Street Corp grew its holdings in shares of Ironwood Pharmaceuticals by 5.2% during the 3rd quarter. State Street Corp now owns 11,454,170 shares of the biotechnology company’s stock worth $118,665,000 after purchasing an additional 567,365 shares during the period. LSV Asset Management grew its holdings in shares of Ironwood Pharmaceuticals by 1.2% during the 2nd quarter. LSV Asset Management now owns 7,670,309 shares of the biotechnology company’s stock worth $81,612,000 after purchasing an additional 92,600 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Ironwood Pharmaceuticals by 21.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 5,611,068 shares of the biotechnology company’s stock worth $59,702,000 after purchasing an additional 1,001,989 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Ironwood Pharmaceuticals by 6.0% during the 1st quarter. Renaissance Technologies LLC now owns 4,637,753 shares of the biotechnology company’s stock worth $48,789,000 after purchasing an additional 263,600 shares during the period.

Ironwood Pharmaceuticals Stock Up 3.6 %

NASDAQ IRWD opened at $9.78 on Friday. The stock has a market cap of $1.53 billion, a PE ratio of -1.57 and a beta of 0.82. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $8.07 and a fifty-two week high of $12.66. The business has a 50 day moving average price of $9.29 and a two-hundred day moving average price of $9.99.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.05). Ironwood Pharmaceuticals had a positive return on equity of 112.29% and a negative net margin of 220.24%. The company had revenue of $113.74 million during the quarter, compared to analysts’ expectations of $112.90 million. During the same quarter in the prior year, the company earned $0.28 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. Sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. StockNews.com assumed coverage on Ironwood Pharmaceuticals in a report on Thursday, October 5th. They set a “hold” rating for the company. TheStreet cut Ironwood Pharmaceuticals from a “b-” rating to a “d-” rating in a report on Tuesday, August 8th. JMP Securities started coverage on Ironwood Pharmaceuticals in a report on Thursday, September 28th. They set an “outperform” rating and a $22.00 target price for the company. Finally, Jefferies Financial Group started coverage on Ironwood Pharmaceuticals in a report on Thursday, November 9th. They issued a “buy” rating and a $21.00 price target for the company.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany bought 36,072 shares of the business’s stock in a transaction on Friday, September 15th. The shares were bought at an average cost of $8.32 per share, with a total value of $300,119.04. Following the transaction, the chief financial officer now directly owns 188,730 shares in the company, valued at approximately $1,570,233.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 13.10% of the stock is currently owned by corporate insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries.